#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Anatabine ameliorates experimental autoimmune thyroiditis."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Esther Wollert"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
# DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
# DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
# DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hp-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
# DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
# DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
# DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
# DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET Citation = {"PubMed", "22807490"}

SET Evidence = "Tobacco smoking has numerous detrimental effects on
human health, but it has also been associated with a
few apparent salutary actions, including the amelioration
of autoimmune (Hashimoto) thyroiditis and ulcerative
colitis."
a(MESH:"Tobacco Smoking") -- path(MESH:"Hashimoto Disease")
a(MESH:"Tobacco Smoking") -- path(MESH:"Colitis, Ulcerative")

SET Evidence = "Smokers in the Third National Health and Nutri-
tion Examination Survey were found to have lower prev-
alence of thyroperoxidase and/or thyroglobulin antibod-
ies than nonsmokers (1)."
a(MESH:"Tobacco Smoking") neg p(HGNC:TPO)

SET Evidence = " Furthermore, anatabine has been recently
shown to inhibit nuclear factor-kB(NF-kB) activation and
reduce neuroinflammation in a mouse model of Alzheimer
disease (15)."
SET MeSHDisease = "Alzheimer Disease"
SET Species = "10090"
a(CHEBI:Anatabine) -| act(p(FPLX:NFkappaB))
SET MeSHAnatomy = "Neurons"
a(CHEBI:Anatabine) -| bp(GO:"inflammatory response")
UNSET MeSHAnatomy
UNSET Species
UNSET MeSHDisease

SET Evidence = "Anatabine significantly decreased the severity of EAT
induced with our standard induction protocol."
#ETA is experimental autoimmune thyroiditis
a(CHEBI:Anatabine) -| path(MESH:"Thyroiditis, Autoimmune")

SET Evidence = "Anatabine
treated mice developed lower levels of thyroglobulin
antibodies than controls on d 14 (P  0.029) and d 21
(P  0.045) (Fig. 2A), suggesting that anatabine atten-
uates the thyroid-specific autoimmune response in-
duced by thyroglobulin immunization."
SET MeSHDisease = "Thyroiditis, Autoimmune"
a(CHEBI:Anatabine) -| a(MESH:Thyroglobulin)
UNSET MeSHDisease

SET Evidence = "Anatabine suppressed the EAT-mediated
increase of IL-1 receptor type 2 (IL-1R2, Figure 3A) and
IL-18 (Fig. 3B), restoring their expression to levels similar
to those seen in normal unimmunized thyroids."
path(MESH:"Thyroiditis, Autoimmune") -> p(HGNC:IL1R2)
a(CHEBI:Anatabine) -| p(HGNC:IL1R2)

SET Evidence = "Anatabine suppressed in a dose-
dependent manner the increase of iNOS and COX2 in-
duced by interferon-g (Fig.4),confirming in vitro its
antiinflammatory properties. The effect seen with inter-
feron-g was also seen when macrophages were stimulated
with lipopolysaccharide (Supplemental Fig. 1)."
#COX2 is PTGS2
p(HGNC:IFNG) -> p(HGNC:NOS2)
p(HGNC:IFNG) -> p(HGNC:PTGS2)
a(CHEBI:Anatabine) -| p(HGNC:NOS2)
a(CHEBI:Anatabine) -| p(HGNC:PTGS2)
a(CHEBI:lipopolysaccharide) -> bp(GO:"macrophage activation")
a(CHEBI:Anatabine) -| bp(GO:"macrophage activation")
